

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/82, 15/52, 9/00, 5/10, G01N 33/50, C12Q 1/68</b>		<b>A3</b>	(11) International Publication Number: <b>WO 00/28053</b>																
			(43) International Publication Date: 18 May 2000 (18.05.00)																
(21) International Application Number: PCT/US99/25950 (22) International Filing Date: 4 November 1999 (04.11.99) (30) Priority Data: 60/107,275                      5 November 1998 (05.11.98)      US (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ALLEN, Stephen, M. [US/US]; 2225 Rosewood Drive, Wilmington, DE 19810 (US). HUANG, Lisa, L. [CN/US]; 1423 Old Wilmington Road, Hockessin, DE 19707 (US). FALCO, Saverio, Carl [US/US]; 1902 Millers Road, Arden, DE 19810 (US). RAFALSKI, Antoni, J. [US/US]; 2028 Longcome Drive, Wilmington, DE 19810 (US). (74) Agent: FEULNER, Gregory, J.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  (88) Date of publication of the international search report: 17 August 2000 (17.08.00)																	
(54) Title: PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS  <table border="0"> <tr> <td>SEQ ID NO:15</td> <td>GIPVIASSGAGTPDHFSEVFEEKRICRACCRHFPPPERGYQSQSVKEHLQEERIEVRI</td> </tr> <tr> <td>SEQ ID NO:02</td> <td>NIPVIASSGAGVADHFSEVFNETNASAAALAGIFHR-KEVPIKAVKEHLLKEGIEVRL</td> </tr> <tr> <td>SEQ ID NO:04</td> <td>-----</td> </tr> <tr> <td>SEQ ID NO:08</td> <td>-----</td> </tr> <tr> <td>SEQ ID NO:06</td> <td>TIPVIASSGAGAVQHFESEIFEKTNASAAALAGIFHR-KEVPILAVKEHLVNAGVEVRV</td> </tr> <tr> <td>SEQ ID NO:10</td> <td>-----</td> </tr> <tr> <td>SEQ ID NO:12</td> <td>-----</td> </tr> <tr> <td>SEQ ID NO:14</td> <td>SIPVIASXGAGAPEHFSEVFYKTNASAAALAGIFHR-KEVPIQSVKEHLLKEGIEVRI</td> </tr> </table> <div style="display: flex; justify-content: space-between;"> <span>541</span> <span>598</span> </div>				SEQ ID NO:15	GIPVIASSGAGTPDHFSEVFEEKRICRACCRHFPPPERGYQSQSVKEHLQEERIEVRI	SEQ ID NO:02	NIPVIASSGAGVADHFSEVFNETNASAAALAGIFHR-KEVPIKAVKEHLLKEGIEVRL	SEQ ID NO:04	-----	SEQ ID NO:08	-----	SEQ ID NO:06	TIPVIASSGAGAVQHFESEIFEKTNASAAALAGIFHR-KEVPILAVKEHLVNAGVEVRV	SEQ ID NO:10	-----	SEQ ID NO:12	-----	SEQ ID NO:14	SIPVIASXGAGAPEHFSEVFYKTNASAAALAGIFHR-KEVPIQSVKEHLLKEGIEVRI
SEQ ID NO:15	GIPVIASSGAGTPDHFSEVFEEKRICRACCRHFPPPERGYQSQSVKEHLQEERIEVRI																		
SEQ ID NO:02	NIPVIASSGAGVADHFSEVFNETNASAAALAGIFHR-KEVPIKAVKEHLLKEGIEVRL																		
SEQ ID NO:04	-----																		
SEQ ID NO:08	-----																		
SEQ ID NO:06	TIPVIASSGAGAVQHFESEIFEKTNASAAALAGIFHR-KEVPILAVKEHLVNAGVEVRV																		
SEQ ID NO:10	-----																		
SEQ ID NO:12	-----																		
SEQ ID NO:14	SIPVIASXGAGAPEHFSEVFYKTNASAAALAGIFHR-KEVPIQSVKEHLLKEGIEVRI																		
(57) Abstract  This invention relates to an isolated nucleic acid fragment encoding a histidine biosynthetic enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the histidine biosynthetic enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the histidine biosynthetic enzyme in a transformed host cell.																			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/25950

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N15/82 C12N15/52 C12N9/00 C12N5/10 G01N33/50 C12Q1/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FUJIMORI K AND OHTA D: "An Arabidopsis cDNA encoding a bifunctional glutamine amidotransferase/cyclase suppresses the histidine auxotrophy of a Saccharomyces cerevisiae his7 mutant" FEBS LETTERS, vol. 428, no. 3, 29 May 1998 (1998-05-29), pages 229-234, XP002136027 the whole document	1-8, 10-15, 17-23
X	KLEM T J AND DAVISSON V J: "Imidazole glycerole phosphate synthase: the glutamine amidotransferase in histidine biosynthesis" BIOCHEMISTRY, vol. 32, 1993, pages 5177-5186, XP002136052 the whole document	16
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <span style="margin-left: 100px;"><input type="checkbox"/> Patent family members are listed in annex.</span>		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-weight: bold;">19 April 2000</div>		Date of mailing of the international search report  <div style="text-align: center; font-weight: bold;">12/05/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-weight: bold;">Oderwald, H</div>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25950

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL 'Online!  EMBL Heidelberg, Germany  AC/ID AW066760,  18 October 1999 (1999-10-18)  WALBOT V: "Maize ESTs from various cDNA  libraries sequenced at Stanford  University"  XP002136029  abstract</p>	<p>1,3-8,  11,  13-15,  17,19,20</p>
P,X	<p>DATABASE EMBL 'Online!  EMBL Heidelberg, Germany  AC/ID AI899863, 28 July 1999 (1999-07-28)  SHOEMAKER R ET AL.: "Glycine max cDNA  clone similar to: glutamine  amidotransferase/cyclase"  XP002136030  abstract</p>	<p>1,3-8,  11,  13-15,  17,19,20</p>
P,X	<p>DATABASE NEW_TREMBL 'Online!  EMBL Heidelberg, Germany  AC/ID CAB36536, 17 June 1999 (1999-06-17)  BEVAN M ET AL.: "Glutamine  amidotransferase/cyclase"  XP002136028  abstract</p>	<p>10</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 25950

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 99 /25950

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: (1-23 partially)

An isolated polynucleotide encoding glutamine amidotransferase from *impatiens* as set forth in SEQ ID NO: 1, a chimeric gene, a host cell, a virus, a polypeptide as set forth in SEQ ID NO: 2, a method of selecting an isolated polynucleotide, a method of obtaining a nucleic acid, a method for evaluating an inhibitory compound, a compositions, an expression cassette, a method for positive selection comprising said polynucleotide.

2. Claims: (1-23 partially)

same as invention 1 but comprising a corn glutamine amidotransferase as set forth in SEQ ID NO: 3-8

3. Claims: (1-23 partially)

same as invention 1 but comprising a rice glutamine amidotransferase as set forth in SEQ ID NO: 9 and 10.

4- Claims: (1-23 partially)

same as invention 1 but comprising a soybean glutamine aminotransferase as set forth in SEQ ID NO: 11-14.

<220>  
 <221> unsure  
 <222> (405)

<220>  
 <221> unsure  
 <222> (441)

<220>  
 <221> unsure  
 <222> (443)

<220>  
 <221> unsure  
 <222> (445)

<220>  
 <221> unsure  
 <222> (453)

<220>  
 <221> unsure  
 <222> (458)

<220>  
 <221> unsure  
 <222> (461)

<220>  
 <221> unsure  
 <222> (475)

<220>  
 <221> unsure  
 <222> (480)

<220>  
 <221> unsure  
 <222> (492)

<220>  
 <221> unsure  
 <222> (494)

<400> 9  
 gacacacacc ccccatactg ccacaagggc cgccgcccgc gccgggagcg atggtcgccg 60  
 ccacctccat caacgccgtc cctgctccg ctggtcggcc gaagcggagg agccagcgcc 120  
 gcggngcctc tacggtcgcc gtgcgcgcgt ccggcgacgc tagcaccgtg acgtgctgg 180  
 actacggcgc gggcaacgtg cgcagcgtgc gcaatgccat ccgccacctc ggtttcggca 240  
 tccgcgacgt gcgcagcccg gagganatcc tcgccgccga ccgcctcgtc ttcccgggg 300  
 tcggcgccctt cgggntcaag ccatggacgt cctcaaccgc ctccgggatg ggcggaacgc 360  
 cttccncgga gtacatccgg caggggaccg ccccttcct cgggnatctg gccttcgggg 420  
 cttccaagct tctccttcgg nantnctaag ggnaagggnag naattggccc cggtnaggcn 480  
 gggcttgggg tntnt 495

<210> 10  
 <211> 87  
 <212> PRT  
 <213> Oryza sativa

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (72)

&lt;400&gt; 10

Met Val Ala Ala Thr Ser Ile Asn Ala Val Pro Cys Ser Ala Gly Arg  
 1 5 10 15

Pro Lys Arg Arg Ser Gln Arg Arg Gly Ala Ser Thr Val Ala Val Arg  
 20 25 30

Ala Ser Gly Asp Ala Ser Thr Val Thr Leu Leu Asp Tyr Gly Ala Gly  
 35 40 45

Asn Val Arg Ser Val Arg Asn Ala Ile Arg His Leu Gly Phe Gly Ile  
 50 55 60

Arg Asp Val Arg Ser Pro Glu Xaa Ile Leu Ala Ala Asp Arg Leu Val  
 65 70 75 80

Phe Pro Gly Val Gly Ala Phe  
 85

&lt;210&gt; 11

&lt;211&gt; 178

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;400&gt; 11

ttgtgacttt gcttgattac ggtgctggca atgttcggag tgtcaggaat gcaatcagat 60  
 tcctcggtt tgacataaaa gatgtgcaaa ctccgcaaga tattctgaat gcaagtcggt 120  
 tagtttttcc tgggtgttga gcatttgctg ctgccatgga ggtgttaagc aaaactgg 178

&lt;210&gt; 12

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Glycine max

&lt;400&gt; 12

Val Thr Leu Leu Asp Tyr Gly Ala Gly Asn Val Arg Ser Val Arg Asn  
 1 5 10 15

Ala Ile Arg Phe Leu Gly Phe Asp Ile Lys Asp Val Gln Thr Pro Gln  
 20 25 30

Asp Ile Leu Asn Ala Ser Arg Leu Val Phe Pro Gly Val Gly Ala Phe  
 35 40 45

Ala Ala Ala Met Glu Val Leu Ser Lys Thr  
 50 55

&lt;210&gt; 13

&lt;211&gt; 671

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (276)



<400> 13  
 gtatgtaaag gatacctaag atgtgcaatt gaagaccata aggggtttcaa gtccagggttc 60  
 aaatggagag gaatatgcat ggtatcaatg tacagttaat gggggacgag agggccggcc 120  
 aattggtgct tatgaactag caaaagcagt tgaagagctt ggtgctggtg aaatactact 180  
 taattgcatt gattgcgacg gtcaagggaa aggatttgat gtagatttaa ttaagttgat 240  
 atcaaagtct gtaagtatcc ctgttatcgc aagtancggt gctggtgctc ctgaacactt 300  
 ctctgaggtg ttctataaaa caaatgcatc agcagcactt gctgctggca tttttcacag 360  
 gaaagaggtg cctattcagt cggtaaaaga gcatttggtg aaggaaggca tagaagttcg 420  
 aatctgatca tatgcattta gtggtaaaat ttttgagatg cacttcataa taatcaaacc 480  
 ttgtacgtta tccctttttg tgtaatctaa cgaagctctc aaaatgtcaa ccttttggat 540  
 catgaaaaga ttttcacaac gagacctttc ctttgtaata tttttaagga aaatatattt 600  
 accatgtgca gcactatctc tgaacatttg ttattacaaa attatttcat gtgtcaaaaa 660  
 aaaaaaaaaa a 671

<210> 14  
 <211> 141  
 <212> PRT  
 <213> Glycine max

<220>  
 <221> UNSURE  
 <222> (92)

<400> 14  
 Tyr Val Lys Asp Pro Asn Asp Val Gln Leu Lys Thr Ile Arg Val Ser  
 1 5 10 15  
 Ser Pro Gly Ser Asn Gly Glu Glu Tyr Ala Trp Tyr Gln Cys Thr Val  
 20 25 30  
 Asn Gly Gly Arg Glu Gly Arg Pro Ile Gly Ala Tyr Glu Leu Ala Lys  
 35 40 45  
 Ala Val Glu Glu Leu Gly Ala Gly Glu Ile Leu Leu Asn Cys Ile Asp  
 50 55 60  
 Cys Asp Gly Gln Gly Lys Gly Phe Asp Val Asp Leu Ile Lys Leu Ile  
 65 70 75 80  
 Ser Asn Ala Val Ser Ile Pro Val Ile Ala Ser Xaa Gly Ala Gly Ala  
 85 90 95  
 Pro Glu His Phe Ser Glu Val Phe Tyr Lys Thr Asn Ala Ser Ala Ala  
 100 105 110  
 Leu Ala Ala Gly Ile Phe His Arg Lys Glu Val Pro Ile Gln Ser Val  
 115 120 125  
 Lys Glu His Leu Leu Lys Glu Gly Ile Glu Val Arg Ile  
 130 135 140

<210> 15  
 <211> 593  
 <212> PRT  
 <213> Arabidopsis thaliana

<400> 15  
 Met Glu Ala Thr Ala Ala Pro Phe Ser Ser Ile Val Ser Ser Arg Gln  
 1 5 10 15

Asn Phe Ser Ser Ser Ser Ser Ile Arg Ala Ser Ser Pro Ala Ser Leu  
                             20                            25                            30  
 Phe Leu Ser Gln Lys Ser Ile Gly Asn Val Asn Arg Lys Phe Lys Ser  
                             35                            40                            45  
 Pro Arg Ser Leu Ser Val Arg Ala Ser Ser Thr Ser Asp Ser Val Val  
                             50                            55                            60  
 Thr Leu Leu Asp Tyr Gly Ala Gly Asn Val Arg Ser Ile Arg Asn Ala  
                             65                            70                            75                            80  
 Leu Arg His Leu Gly Phe Ser Ile Lys Asp Val Gln Thr Pro Gly Asp  
                             85                            90                            95  
 Ile Leu Asn Ala Asp Arg Leu Ile Phe Pro Gly Val Gly Pro Phe Ala  
                             100                            105                            110  
 Pro Ala Met Asp Val Leu Asn Arg Thr Gly Met Ala Glu Ala Leu Cys  
                             115                            120                            125  
 Lys Tyr Ile Glu Asn Asp Arg Pro Phe Leu Gly Ile Cys Leu Gly Leu  
                             130                            135                            140  
 Gln Leu Leu Phe Asp Ser Ser Glu Gln Asn Gly Pro Val Lys Gly Leu  
                             145                            150                            155                            160  
 Gly Val Ile Pro Gly Ile Val Gly Arg Phe Asp Ala Ser Ala Gly Ile  
                             165                            170                            175  
 Arg Val Pro His Ile Gly Trp Asn Ala Leu Gln Val Gly Lys Asp Ser  
                             180                            185                            190  
 Glu Ile Leu Asp Asp Val Gly Asn Arg His Val Tyr Phe Val His Ser  
                             195                            200                            205  
 Tyr Arg Ala Ile Pro Ser Asp Glu Asn Lys Asp Trp Ile Ser Ser Thr  
                             210                            215                            220  
 Cys Asn Tyr Gly Glu Ser Phe Ile Ser Ser Ile Arg Arg Gly Asn Val  
                             225                            230                            235                            240  
 His Ala Val Gln Phe His Pro Glu Lys Ser Gly Glu Val Gly Leu Ser  
                             245                            250                            255  
 Val Leu Arg Arg Phe Leu His Pro Lys Leu Pro Ala Thr Gln Lys Pro  
                             260                            265                            270  
 Met Glu Gly Lys Ala Ser Lys Leu Ala Lys Arg Val Ile Ala Cys Leu  
                             275                            280                            285  
 Asp Val Arg Thr Asn Asp Lys Gly Asp Leu Val Val Thr Lys Gly Asp  
                             290                            295                            300  
 Gln Tyr Asp Val Arg Glu Gln Ser Asn Glu Asn Glu Val Arg Asn Leu  
                             305                            310                            315                            320  
 Gly Lys Pro Val Asp Leu Ala Gly Gln Tyr Tyr Lys Asp Gly Ala Asp  
                             325                            330                            335

Glu Ile Ser Phe Leu Asn Ile Thr Gly Phe Arg Asp Phe Pro Leu Gly  
 340 345 350  
 Asp Leu Pro Met Ile Gln Val Leu Arg Gln Thr Ser Lys Asn Val Phe  
 355 360 365  
 Val Pro Leu Thr Val Gly Gly Gly Ile Arg Asp Phe Thr Asp Ala Ser  
 370 375 380  
 Gly Arg Tyr Tyr Ser Ser Leu Glu Val Ala Ala Glu Tyr Phe Arg Ser  
 385 390 395 400  
 Gly Ala Asp Lys Met Ser Ile Gly Ser Asp Ala Val Phe Ala Ala Glu  
 405 410 415  
 Glu Phe Ile Lys Ser Gly Val Lys Thr Gly Lys Ser Ser Leu Glu Gln  
 420 425 430  
 Ile Ser Arg Val Tyr Gly Asn Gln Ala Val Val Val Ser Ile Asp Pro  
 435 440 445  
 Arg Arg Val Tyr Val Asn His Pro Asp Asp Val Pro Tyr Lys Val Ile  
 450 455 460  
 Arg Val Thr Asn Pro Gly Pro Asn Gly Glu Glu Tyr Ala Trp Tyr Gln  
 465 470 475 480  
 Cys Thr Val Ser Gly Gly Gln Glu Gly Arg Pro Ile Gly Ala Phe Glu  
 485 490 495  
 Leu Ala Lys Ala Val Glu Glu Leu Gly Ala Gly Glu Ile Leu Leu Asn  
 500 505 510  
 Cys Ile Asn Cys Asp Gly Gln Gly Lys Gly Phe Asp Ile Asp Leu Val  
 515 520 525  
 Lys Leu Ile Ser Asp Ser Val Gly Ile Pro Val Ile Ala Ser Ser Gly  
 530 535 540  
 Ala Gly Thr Pro Asp His Phe Ser Glu Val Phe Glu Glu Asp Lys Arg  
 545 550 555 560  
 Ile Cys Arg Ala Cys Cys Arg His Phe Pro Pro Glu Arg Gly Tyr Gln  
 565 570 575  
 Ser Gln Ser Val Lys Glu His Leu Gln Glu Glu Arg Ile Glu Val Arg  
 580 585 590  
 Ile